Inhibition of ACE-mediated NOX4-related OS and NLRP3 inflammasome activation in cardiac fibroblasts improves diabetic cardiac fibrosis, thereby providing a potential therapeutic approach for treating DCM. This evidence concerns the gene NOX4 and familial dilated cardiomyopathy.